摘要
目的探讨肝康IV号抗脂肪肝发生脂质过氧化损伤效果,为临床治疗脂肪肝提供实验依据。方法64只Wistar大鼠随机分为6组,采用高脂饮食和白酒复合因数复制大鼠脂肪肝模型,同时分别用肝康IV号低、中、高剂量和东宝肝泰进行干预,模型组和正常对照组用生理盐水灌胃,于第8周末处死动物取血查肝功能,取肝脏制备10%的肝匀浆查超氧化物歧化酶(SOD)、丙二醛(MDA)。结果肝康IV号治疗组可显著降低血清AST和ALT,提高肝组织SOD含量,降低肝组织MDA的水平,明显优于东宝肝泰治疗组和模型组(P<0.05)。结论肝康IV号可以提高肝脏抗脂质过氧化损伤的能力,阻止脂肪肝的发展。
Objective To explore the effect of LPO-resistance with Gankang Ⅳ（GKⅣ） on fatty liver to provide the experimental basis for the clinical therapy of fatty liver. Methods： 64 wistar rats were divided randomly into six group. The animal model of fatty liver was duplicated with high fat diet and alcohol. All the treatment groups were intervened by its own medicine,Gankang IV（GKIV）and DongBao GanTai（DBGT）. After 8 weeks,all animals were killed to take the blood 2ml and check the liver function immediately. Live tissue in animal was extracted to be made into the 10% hepatic tissue fluid,tested the SOD and MDA. Results：The AST and ALT contents in serum decreased significantly and The SOD/MDA contents in hepatic tissue increased/decreased significantly in GKIV group than that of model group and DBGT group （P （0. 05）. Conclusion： GKIV can promote the LPO-resistance competence of liver and prevent fatty liver developing.
出处
《湖北中医学院学报》
2006年第4期7-8,共2页
Journal of Hubei College of Traditional Chinese Medicine
